Trastuzumab deruxtecan for adults with advanced breast cancer
Official title: Trastuzumab Deruxtecan in Patients With Advanced Breast Cancer: a Real-world Study
Run by RenJi Hospital · NCT07180264 · Data updated 2026-11-12
This trial tests trastuzumab deruxtecan in adults with advanced breast cancer to see if it is safe and works well.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 118 (estimated) |
| Sponsor | RenJi Hospital Academic / other |
| Drugs / interventions | trastuzumab |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | August 28, 2025 |
| Main results expected | February 2027 |
| Study ends | February 2029 |
| Registry record updated | November 18, 2025 |
| Trial ID | NCT07180264 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with advanced breast cancer who meet guideline indications for trastuzumab deruxtecan, have ECOG 0–1, and are not pregnant or breastfeeding.
✕Probably not a fit
Patients who are pregnant or breastfeeding, have ECOG ≥2, or who are not planned to receive trastuzumab deruxtecan are unlikely to benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study at Renji Hospital follows adults with advanced breast cancer who are planned to receive trastuzumab deruxtecan according to current guidelines. Eligible patients are 18 or older with ECOG performance status 0–1 and are followed during routine care for safety, adverse events, and clinical response. Data collected include dosing, treatment duration, laboratory and imaging results, and clinical outcomes without experimental treatment assignments. Pregnant and lactating people are excluded from participation.
Why it matters
Potential benefit: If successful, the study could provide real-world safety and effectiveness data to help clinicians refine use of trastuzumab deruxtecan and inform patient care decisions.
How similar studies have gone: Large randomized programs (the DESTINY trials) have demonstrated substantial antitumor activity and clinical benefit for trastuzumab deruxtecan in metastatic HER2‑positive and HER2‑low breast cancer, and this observational work aims to add real‑world confirmation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged ≥18 and older * Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan * ECOG 0-1 Exclusion Criteria: * During pregnancy and lactation
Where it's running
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China Recruiting
Study contacts
- Principal investigator: Wenjin Yin, M.D. — Renji Hospital,School of Medicine, Shanghai Jiaotong University
- Study coordinator: Wenjin Yin, M.D.
- Email: yinwenjin@renji.com
- Phone: 86(21)68385569
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Trastuzumab rezetecan followed by CDK4/6 inhibitor plus hormone therapy for HR+/HER2‑low/ultra‑low advanced breast cancer
This trial will test whether starting with trastuzumab rezetecan and then switching to a CDK4/6 inhibitor plus endocrine therapy helps women with HR-positive, HER2-low or ultra-low advanced breast cancer live longer without disease progression.
-
Trastuzumab deruxtecan versus CDK4/6 inhibitor plus hormone therapy as first-line treatment for HR-positive, HER2-low non-luminal advanced breast cancer.
This trial will see if trastuzumab deruxtecan (T-DXd) works better than a CDK4/6 inhibitor plus endocrine (hormone) therapy as first-line treatment for adults with HR-positive, HER2-low advanced breast cancer that is classified as non-luminal by gene profiling.
-
Combining Eribulin and a Trastuzumab-biosimilar for Advanced HER2-positive Breast Cancer
This study is testing if combining two cancer drugs, eribulin and a trastuzumab-biosimilar, can help people with advanced HER2-positive breast cancer who have already tried other treatments.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Imaging study of [68Ga]Ga-DWJ155 in adults with solid tumors
This trial tests a new radioligand imaging agent, [68Ga]Ga-DWJ155, to see how well it images tumors and how safe it is in adults with advanced solid cancers.
-
Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer
This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.